The prognostic value of the direct bilirubin to albumin ratio in critically ill patients with cirrhosis: Insights from MIMIC-IV database

直接胆红素/白蛋白比值在危重肝硬化患者中的预后价值:来自MIMIC-IV数据库的启示

阅读:1

Abstract

BACKGROUND: Patients with severe cirrhosis are at a higher risk of mortality. This study aimed to investigate the association between the direct bilirubin-to-albumin ratio (DBAR) and 28-day mortality in critically ill cirrhotic patients using data from the publicly available MIMIC-IV database. METHODS: This study explores DBAR's relationship with 28-day mortality in severe cirrhosis patients. We first conducted univariate and multivariate analyses to identify independent risk factors. Then, we used Kaplan-Meier (KM) survival analysis to assess DBAR's link with survival time and created KM curves. DBAR's predictive accuracy was evaluated using Receiver Operating Characteristic (ROC) analysis, and the relationship was examined using restricted cubic spline modeling and subgroup analyses. RESULT: This study enrolled 509 cirrhotic patients with in-hospital and ICU mortality rates of 22.3% and 14.3%, respectively. Univariate and multivariate analyses revealed a significant association between DBAR and 28-day mortality risk, with a hazard ratio of 1.16 (95% CI: 1.10-1.24, p < 0.001), confirming DBAR as an independent risk factor for short-term prognosis. DBAR demonstrated good predictive accuracy for 28-day mortality (AUC = 0.702, 95% CI: 0.650-0.753). Patients were divided into low-risk (DBAR < 4) and high-risk (DBAR ≥ 4) groups, with the high-risk group showing a hazard ratio of 3.05 (95% CI 1.87-4.97, p < 0.001) after multivariate adjustment. Restricted cubic spline (RCS) analysis identified a nonlinear relationship between DBAR and 28-day prognosis (p-Nonlinear = 0.022, p < 0.001). Subgroup analysis showed no interaction between DBAR and most subgroups. CONCLUSION: The DBAR scoring system offers an efficient and user-friendly approach for assessing prognosis in critically ill cirrhotic patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。